Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday.

Other research analysts have also recently issued reports about the company. Bank of America raised their target price on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. Piper Sandler reiterated an “overweight” rating and set a $20.00 target price (up from $19.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, May 13th. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 5th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, July 10th. Finally, Argus upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.56.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded up $0.30 on Thursday, hitting $16.81. 10,311,489 shares of the company were exchanged, compared to its average volume of 10,293,612. The company’s 50 day moving average price is $16.75 and its two-hundred day moving average price is $14.48. The firm has a market capitalization of $19.03 billion, a price-to-earnings ratio of -40.99, a PEG ratio of 1.49 and a beta of 0.90. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.61 and a current ratio of 0.89. Teva Pharmaceutical Industries has a one year low of $8.06 and a one year high of $17.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $3.82 billion for the quarter, compared to the consensus estimate of $3.70 billion. Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. Research analysts expect that Teva Pharmaceutical Industries will post 2.32 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 15,500 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the transaction, the chief accounting officer now owns 17,814 shares in the company, valued at approximately $299,275.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CAO Amir Weiss sold 15,500 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total transaction of $260,400.00. Following the sale, the chief accounting officer now directly owns 17,814 shares of the company’s stock, valued at $299,275.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 549,719 shares of company stock worth $9,353,736. 0.55% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently added to or reduced their stakes in TEVA. Janney Montgomery Scott LLC lifted its holdings in Teva Pharmaceutical Industries by 13.6% in the first quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after buying an additional 164,614 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Teva Pharmaceutical Industries by 705.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock worth $6,051,000 after purchasing an additional 507,568 shares during the last quarter. QRG Capital Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 53.7% during the first quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock worth $2,028,000 after purchasing an additional 50,247 shares during the period. Capital Wealth Planning LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter valued at about $2,169,000. Finally, Public Employees Retirement Association of Colorado lifted its stake in Teva Pharmaceutical Industries by 1,382.8% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock valued at $2,671,000 after buying an additional 238,573 shares during the period. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.